CA2789736A1 - A tolerable and minimally invasive skin electroporation device - Google Patents

A tolerable and minimally invasive skin electroporation device Download PDF

Info

Publication number
CA2789736A1
CA2789736A1 CA2789736A CA2789736A CA2789736A1 CA 2789736 A1 CA2789736 A1 CA 2789736A1 CA 2789736 A CA2789736 A CA 2789736A CA 2789736 A CA2789736 A CA 2789736A CA 2789736 A1 CA2789736 A1 CA 2789736A1
Authority
CA
Canada
Prior art keywords
electrodes
tissue
electrical potential
voltage generator
electroporation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2789736A
Other languages
English (en)
French (fr)
Inventor
Kate Broderick
Jay Mccoy
Stephen V. Kemmerrer
Feng Lin
Rune Kjeken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inovio Pharmaceuticals Inc
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of CA2789736A1 publication Critical patent/CA2789736A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0502—Skin piercing electrodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2789736A 2010-03-01 2011-03-01 A tolerable and minimally invasive skin electroporation device Pending CA2789736A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30942210P 2010-03-01 2010-03-01
US61/309,422 2010-03-01
PCT/US2011/026701 WO2011109406A1 (en) 2010-03-01 2011-03-01 A tolerable and minimally invasive skin electroporation device

Publications (1)

Publication Number Publication Date
CA2789736A1 true CA2789736A1 (en) 2011-09-09

Family

ID=44542539

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2789736A Pending CA2789736A1 (en) 2010-03-01 2011-03-01 A tolerable and minimally invasive skin electroporation device

Country Status (14)

Country Link
US (2) US11565107B2 (enExample)
EP (1) EP2542300B1 (enExample)
JP (1) JP5706451B2 (enExample)
KR (1) KR101872408B1 (enExample)
CN (1) CN102905755B (enExample)
AU (1) AU2011223753B2 (enExample)
CA (1) CA2789736A1 (enExample)
DK (1) DK2542300T3 (enExample)
EA (1) EA025705B1 (enExample)
ES (1) ES2594498T3 (enExample)
MX (1) MX2012009986A (enExample)
PL (1) PL2542300T3 (enExample)
PT (1) PT2542300T (enExample)
WO (1) WO2011109406A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3473296T3 (da) 2011-06-28 2020-11-09 Inovio Pharmaceuticals Inc Minimalt invasiv dermal elektroporeringsenhed
AU2015203882C1 (en) * 2011-06-28 2017-09-21 Inovio Pharmaceuticals, Inc. A minimally invasive dermal electroporation device
EP3010582B1 (en) 2013-06-21 2021-04-28 Newsouth Innovations Pty Limited Method and apparatus for close-field electroporation
CN104689478A (zh) * 2013-12-09 2015-06-10 深圳市瑞吉思科技有限公司 细胞再生仪
CN103861202B (zh) 2014-03-18 2016-06-01 苏州壹达生物科技有限公司 一种利用空心电极针电穿孔给药的装置
DK3277368T3 (da) * 2015-03-31 2020-07-27 Oncosec Medical Inc Systemer til forbedret vævsregistreringsbaseret elektroporering
PT3397337T (pt) 2015-12-30 2020-11-24 Inovio Pharmaceuticals Inc Dispositivo de eletroporação com conjunto de agulhas destacável com sistema de bloqueio
US11390840B2 (en) * 2016-09-30 2022-07-19 University Of Florida Research Foundation, Inc. Systems and methods including porous membrane for low-voltage continuous cell electroporation
CN107890608A (zh) * 2017-12-01 2018-04-10 王嘉浩 淋巴细胞增升仪
CN113613711B (zh) * 2019-02-04 2024-09-17 新泽西州立罗格斯大学 使用微电极进行组织电转移的装置
US11071860B2 (en) 2019-02-06 2021-07-27 Oncosec Medical Incorporated Systems and methods for detecting fault conditions in electroporation therapy
BR102019013578A2 (pt) * 2019-06-28 2021-01-05 Eqt Equipamentos E Tecnologia Ltda. Ponta aplicadora de eletroporação para procedimento de eletroquimioterapia
EP4121161A4 (en) 2020-03-20 2024-10-16 Inovio Pharmaceuticals, Inc. VACUUM-ASSISTED ELECTROPORATION DEVICES AND CORRESPONDING SYSTEMS AND METHODS
KR102576604B1 (ko) 2021-02-16 2023-09-08 주식회사 밀알 의료용 정밀 약물주입 및 전기천공 융합 전극
KR20220159203A (ko) 2021-05-25 2022-12-02 주식회사 밀알 의료용 정밀 약물주입 및 전기천공 융합 전극

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994287A (en) * 1974-07-01 1976-11-30 Centre De Recherche Industrielle Du Quebec Trocar
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6277116B1 (en) * 1994-05-06 2001-08-21 Vidaderm Systems and methods for shrinking collagen in the dermis
WO1998000193A1 (en) * 1996-07-03 1998-01-08 Altea Technologies, Inc. Multiple mechanical microporation of skin or mucosa
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
WO1998043702A2 (en) 1997-04-03 1998-10-08 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
US6241701B1 (en) * 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
TW368420B (en) * 1997-11-04 1999-09-01 Genetronics Inc Apparatus and method for transdermal molecular delivery by applying sufficient amplitude of electric field to induce migration of molecules through pores in the stratum corneum
US7922709B2 (en) * 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
WO2000044438A1 (en) 1999-01-28 2000-08-03 Cyto Pulse Sciences, Inc. Delivery of macromolecules into cells
US6678558B1 (en) * 1999-03-25 2004-01-13 Genetronics, Inc. Method and apparatus for reducing electroporation-mediated muscle reaction and pain response
US7113821B1 (en) 1999-08-25 2006-09-26 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery
US20070016268A1 (en) 2000-01-07 2007-01-18 John Carter Percutaneous electrode array
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
AU2003226605A1 (en) * 2002-04-19 2003-11-03 Transpharma Medical Ltd. Handheld transdermal drug delivery and analyte extraction
US20060036210A1 (en) 2004-06-30 2006-02-16 Lei Zhang Modular electroporation device with disposable electrode and drug delivery components
US20100168501A1 (en) * 2006-10-02 2010-07-01 Daniel Rogers Burnett Method and apparatus for magnetic induction therapy
CA3063263C (en) * 2006-02-11 2024-01-16 Genetronics, Inc. Device and method for single-needle in vivo electroporation
CN101563132A (zh) * 2006-10-17 2009-10-21 Vgx药品公司 电穿孔装置及用其进行哺乳动物细胞电穿孔的方法
EP2111252A4 (en) 2007-01-31 2010-12-01 Adam Heller MANAGEMENT OF PAIN BY ELECTROCHEMICAL PATHWAY

Also Published As

Publication number Publication date
ES2594498T3 (es) 2016-12-20
JP2013521058A (ja) 2013-06-10
EP2542300A4 (en) 2013-11-13
KR101872408B1 (ko) 2018-06-28
EA201201203A1 (ru) 2013-04-30
EP2542300B1 (en) 2016-08-10
US12491361B2 (en) 2025-12-09
CN102905755B (zh) 2016-03-09
US11565107B2 (en) 2023-01-31
JP5706451B2 (ja) 2015-04-22
AU2011223753A1 (en) 2012-09-13
DK2542300T3 (en) 2016-11-28
US20130066296A1 (en) 2013-03-14
KR20130020662A (ko) 2013-02-27
US20230145532A1 (en) 2023-05-11
PL2542300T3 (pl) 2017-06-30
WO2011109406A1 (en) 2011-09-09
PT2542300T (pt) 2016-11-14
MX2012009986A (es) 2012-11-21
BR112012021805A2 (pt) 2016-05-17
EA025705B1 (ru) 2017-01-30
AU2011223753B2 (en) 2014-06-26
EP2542300A1 (en) 2013-01-09
CN102905755A (zh) 2013-01-30
HK1181339A1 (zh) 2013-11-08

Similar Documents

Publication Publication Date Title
US12491361B2 (en) Tolerable and minimally invasive skin electroporation device
JP6955076B2 (ja) 低侵襲表皮電気穿孔装置
Zhao et al. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization
CN105939730B (zh) MERS-CoV疫苗
CN106794263B (zh) 具有抗原和作为佐剂的白细胞介素-21的疫苗
Broderick et al. Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device
US12622868B2 (en) Devices, systems, and methods for facilitating tissue delivery of drug
Kichaev et al. Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses
CN111012905B (zh) 具有作为佐剂的白介素-33的疫苗
Schultheis et al. Characterization of guinea pig T cell responses elicited after EP-assisted delivery of DNA vaccines to the skin
KR102599298B1 (ko) 전기천공을 사용하여 지방 조직의 생체내 형질감염을 최소로 침습성으로 하기 위한 방법 및 장치
CN102892461B (zh) 口部粘膜电穿孔装置及其用途
Broderick et al. Piezoelectric permeabilization of mammalian dermal tissue for in vivo DNA delivery leads to enhanced protein expression and increased immunogenicity
HK1181339B (en) A tolerable and minimally invasive skin electroporation device
BR112012021805B1 (pt) Dispositivo de eletroporação capaz de fornecer a um indivíduo um potencial elétrico tolerável às camadas do tecido epidérmico entre o estrato córneo e as camadas basais
BR122022000530B1 (pt) Dispositivo de eletroporação e matriz do mesmo capaz de fornecer a um indivíduo um potencial elétrico tolerável ao tecido epidérmico que resulta em eletroporação de células no dito tecido
HK40028403A (en) Vaccines with interleukin-33 as an adjuvant
Misra Vaccine Delivery by Transdermal Electroporation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160118

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240909

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241220

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250110

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250208

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250208

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260413

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20260608

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260608

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260702

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20260702

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260702

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260702

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260702